4baseCare, India’s leading precision oncology startup, has partnered with Owkin, a global leader in federated AI for medical research, to advance inclusive cancer research. The collaboration leverages Owkin’s federated learning technology and multimodal AI capabilities with 4baseCare’s extensive clinico-genomic data from Indian patients, aiming to develop more representative, equitable AI models for cancer diagnosis, treatment selection, and prognosis.
Glimpse:
Through federated learning, the partnership enables collaborative AI training across institutions without sharing sensitive patient data. It focuses on building India-centric models that better capture the genetic and clinical diversity of Indian cancer patients addressing gaps in global datasets that often underrepresent non-Western populations. The joint effort targets improved precision in identifying actionable mutations, predicting therapy response, and supporting clinical trial matching for underrepresented groups.
4baseCare and Owkin have announced a strategic collaboration to co-develop next-generation AI solutions for cancer research with a strong emphasis on inclusivity and representation. The partnership combines 4baseCare’s large-scale clinico-genomic dataset derived from thousands of Indian cancer patients—with Owkin’s pioneering federated learning platform, which allows AI model training across multiple institutions while keeping patient data secure and local.
Key objectives of the collaboration include:
Building diverse, representative AI models overcoming biases in existing global oncology datasets that predominantly reflect Western populations Federated learning approach enabling joint model development without centralizing sensitive health data, ensuring privacy and compliance with Indian regulations Multimodal AI advancements integrating genomics, histopathology slides, clinical records, and imaging to improve mutation prediction, therapy matching, and survival forecasting Support for clinical trial equity identifying suitable Indian patients for global trials and accelerating recruitment for underrepresented cohorts Real-world evidence generation producing India-specific insights to inform treatment guidelines and regulatory decisions
4baseCare brings one of the largest clinico-genomic repositories from Indian patients, capturing unique disease biology, treatment responses, and socioeconomic factors. Owkin contributes its federated learning expertise (used in major international consortia) and multimodal AI capabilities that excel at integrating diverse data types.
The partnership addresses a critical gap: most AI oncology tools are trained on datasets that underrepresent Indian and South Asian populations, leading to reduced accuracy and equity issues. By combining local data with global federated methods, the collaboration aims to create more robust, generalizable models that benefit patients worldwide while prioritizing India’s needs.
This alliance reinforces India’s growing role in global precision oncology research and highlights the power of federated learning to enable collaborative innovation without compromising data sovereignty.
“True precision oncology must reflect the diversity of patients everywhere. With Owkin’s federated AI, we can train inclusive models that truly understand Indian cancer biology without ever moving sensitive data.”
By
HB Team
Related News
